Shire plc (SHPG) and Synlogic Inc. (NASDAQ:SYBX) Comparing side by side

Both Shire plc (NASDAQ:SHPG) and Synlogic Inc. (NASDAQ:SYBX) are Biotechnology companies, competing one another. We will compare their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Shire plc N/A 0.00 N/A 7.94 21.44
Synlogic Inc. 2.52M 89.98 48.20M -2.29 0.00

Table 1 highlights Shire plc and Synlogic Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the return on equity, return on assets and net margins of both companies.

Net Margins Return on Equity Return on Assets
Shire plc 0.00% 13% 7.2%
Synlogic Inc. -1,912.70% -39.1% -34.7%

Liquidity

0.9 and 0.5 are the respective Current Ratio and a Quick Ratio of Shire plc. Its rival Synlogic Inc.’s Current and Quick Ratios are 15.2 and 15.2 respectively. Synlogic Inc. has a better chance of clearing its pay short and long-term debts than Shire plc.

Dividends

Shire plc pays out a $0.35 per share dividend on a yearly basis and it also offers 0.2% dividend yield. No dividend is paid out by Synlogic Inc.

Analyst Ratings

The table delivered features the ratings and recommendations for Shire plc and Synlogic Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Shire plc 0 1 0 2.00
Synlogic Inc. 0 0 0 0.00

Shire plc’s upside potential currently stands at 9.38% and an $196 average target price.

Institutional & Insider Ownership

Shire plc and Synlogic Inc. has shares held by institutional investors as follows: 22.9% and 82.5%. Insiders held 0.1% of Shire plc shares. On the other hand, insiders held about 0.2% of Synlogic Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Shire plc -3.11% -5.99% 1.27% 6.01% 18.67% 9.67%
Synlogic Inc. -11.63% -6.64% -41.52% -19.05% -28.99% -22.47%

For the past year Shire plc had bullish trend while Synlogic Inc. had bearish trend.

Summary

Shire plc beats Synlogic Inc. on 9 of the 12 factors.

Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE and ADYNOVATE/ADYNOVI for hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand Disease; FEIBA to treat hemophilia A and B patients with inhibitors; CINRYZE and FIRAZYR for hereditary angioedema; ELAPRASE to treat hunter syndrome; REPLAGAL for Fabry disease; and VPRIV to treat type 1 Gaucher disease. The company marketed products also comprise of VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention-deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of LIALDA/MEZAVANT for ulcerative colitis; GATTEX/REVESTIVE to treat short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA to treat dry eye disease. The company markets its products through wholesalers, distribution centers, and pharmacies. It has collaborative and other licensing arrangements with Pfizer Inc.; Precision BioSciences; Symphogen; Merrimack Pharmaceuticals, Inc.; Coherus Biosciences, Inc.; Momenta Pharmaceuticals, Inc.; and SFJ Pharmaceuticals Group. Shire plc was founded in 1986 and is based in Dublin, Ireland.

Synlogic, Inc. develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company is based in Cambridge, Massachusetts.